Broccoli Compound Sulforaphane Shows Promise Against Friedreich Ataxia, a Rare Fatal Nerve Disease

Friedreich ataxia takes things from a child in a particular order: coordination first, then the ability to walk, then speech. It is a genetic disease in which nerve cells in the brain and spinal cord gradually break down. It can shorten life expectancy, and there is no cure. About 200 Australians are living with it.

Now researchers at Swinburne University report that a compound found naturally in broccoli may offer a way to push back against it. The compound is called sulforaphane. In their study, it raised levels of frataxin, the protein that people with Friedreich ataxia do not make enough of. The team also found that it helped protect vulnerable nerve cells from damage.

Frataxin matters because it helps keep cells working properly, especially cells with heavy energy demands, such as nerve cells. In Friedreich ataxia, a genetic defect cuts production of the protein, and that shortfall contributes to the progressive damage that defines the illness. Raising frataxin therefore goes after the underlying problem rather than only its symptoms.

The researchers say sulforaphane may do more than that. Research indicates it also influences several biological processes tied to how the disease advances, including cellular stress and inflammation. Tackling several sources of damage at once is part of what makes the compound an appealing candidate for further study.

The lead researcher, Associate Professor Faith Kwa of Swinburne, points to children as the group with the most to gain. They make up a large share of those affected, she says, and no treatment is currently approved specifically for pediatric patients. She describes the disease as one that "progressively steals a child's ability to walk, speak, play, and ultimately survive." She says the compound could target the underlying cause while being affordable and accessible worldwide, bringing families closer to a future of better quality of life, more independence and improved long-term survival.

Accessibility is a central part of the case. Sulforaphane is not an unfamiliar substance. It has an established safety record in both children and adults, and purified, biologically active forms are already sold commercially. If clinical trials show it works against Friedreich ataxia, those facts could speed its path to patients and keep costs down.

That "if" carries real weight. The findings are promising, but the source is clear that clinical trials are still needed to establish whether the compound is effective in people, and that further research is essential before anyone can say whether the results will translate into meaningful benefit.

Paying for those trials is its own obstacle. Kwa explains that because so few people have Friedreich ataxia, public awareness is low, and that makes it harder to attract funding for research. The Swinburne team is seeking financial support to run trials that would test whether sulforaphane has the same effects in patients. "Sulforaphane already has an established safety record in children and adults," she says, adding that if trials succeed, rollout could move quickly.

For families facing a progressive illness with no cure, even modest gains in daily functioning and independence could matter. Kwa says that if the work raises awareness or improves one person's quality of life, the effort will have been worthwhile. What to watch next is whether the team secures the funding to move from laboratory findings to a patient trial.